Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis.

Gastric cancer Hispanic The National Cancer Database (NCDB) ethnicity propensity score matching

Journal

Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 14 04 2021
accepted: 30 06 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 18 9 2021
Statut: ppublish

Résumé

The burden of gastric cancer involving Hispanic patients in the United States is growing as both the population and the incidence of gastric cancer in this group increases. This burden is compounded by presentation with advanced disease and socioeconomic challenges shaping cancer care. We sought to describe the demographics, socioeconomic factors, treatment, and survival experience of Hispanic patients with gastric adenocarcinoma. Patients with gastric adenocarcinoma diagnosed between 2004 and 2015 (n=90,737) in the National Cancer Database were retrospectively identified. Patients of Hispanic ethnicity were compared against non-Hispanic white patients. Surgical cohort was further analyzed, and 1:1 propensity score matching was used to balance covariates between Hispanic and non-Hispanic white surgical patients. Survival was compared using Kaplan-Meier method. Cox regression was used to determine prognostic factors for survival. Compared to non-Hispanic white patients, Hispanic patients are more likely to be younger, female, and healthier. They were more likely to be uninsured, reside in poorer neighborhoods and reside in areas with lower rates of education. Hispanic patients were more likely to live in a metropolitan area, travel shorter distances for healthcare, and receive treatment at an academic and high volume centers. Hispanic patients were more likely to have higher stage disease presentation, higher grade tumors, lymphovascular invasion, and poorly cohesive adenocarcinoma. Hispanic patients were more likely to receive surgery, but less likely to receive adjuvant therapy. In Cox regression of all patients, unmatched surgical patients, and matched surgical patients, Hispanic ethnicity was an independent prognostic factor of improved survival. Hispanic patients with gastric adenocarcinoma present with several unfavorable clinicopathologic and socioeconomic factors. Paradoxically, these patients demonstrate improved survival. Further study is warranted to characterize disease biology in this population.

Sections du résumé

BACKGROUND BACKGROUND
The burden of gastric cancer involving Hispanic patients in the United States is growing as both the population and the incidence of gastric cancer in this group increases. This burden is compounded by presentation with advanced disease and socioeconomic challenges shaping cancer care. We sought to describe the demographics, socioeconomic factors, treatment, and survival experience of Hispanic patients with gastric adenocarcinoma.
METHODS METHODS
Patients with gastric adenocarcinoma diagnosed between 2004 and 2015 (n=90,737) in the National Cancer Database were retrospectively identified. Patients of Hispanic ethnicity were compared against non-Hispanic white patients. Surgical cohort was further analyzed, and 1:1 propensity score matching was used to balance covariates between Hispanic and non-Hispanic white surgical patients. Survival was compared using Kaplan-Meier method. Cox regression was used to determine prognostic factors for survival.
RESULTS RESULTS
Compared to non-Hispanic white patients, Hispanic patients are more likely to be younger, female, and healthier. They were more likely to be uninsured, reside in poorer neighborhoods and reside in areas with lower rates of education. Hispanic patients were more likely to live in a metropolitan area, travel shorter distances for healthcare, and receive treatment at an academic and high volume centers. Hispanic patients were more likely to have higher stage disease presentation, higher grade tumors, lymphovascular invasion, and poorly cohesive adenocarcinoma. Hispanic patients were more likely to receive surgery, but less likely to receive adjuvant therapy. In Cox regression of all patients, unmatched surgical patients, and matched surgical patients, Hispanic ethnicity was an independent prognostic factor of improved survival.
CONCLUSIONS CONCLUSIONS
Hispanic patients with gastric adenocarcinoma present with several unfavorable clinicopathologic and socioeconomic factors. Paradoxically, these patients demonstrate improved survival. Further study is warranted to characterize disease biology in this population.

Identifiants

pubmed: 34532090
doi: 10.21037/jgo-21-207
pii: jgo-12-04-1308
pmc: PMC8421888
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1308-1325

Informations de copyright

2021 Journal of Gastrointestinal Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jgo-21-207). The authors have no conflicts of interest to declare.

Références

Cochrane Database Syst Rev. 2015 Aug 12;(8):CD001964
pubmed: 26267122
Lancet Oncol. 2010 May;11(5):439-49
pubmed: 20409751
J Clin Oncol. 2005 May 1;23(13):3094-103
pubmed: 15860869
Korean J Intern Med. 2015 Nov;30(6):747-58
pubmed: 26552450
J Gastroenterol Hepatol. 2012 May;27(5):928-34
pubmed: 22142434
Eur J Surg Oncol. 2002 Apr;28(3):214-9
pubmed: 11944952
Ann Surg. 2009 Dec;250(6):878-87
pubmed: 19855261
Surgery. 2003 Oct;134(4):720-7; discussion 727-9
pubmed: 14605635
Cancer. 2000 Nov 1;89(9):1883-92
pubmed: 11064344
Jpn J Clin Oncol. 2018 Jul 1;48(7):673-683
pubmed: 29889263
Ann Pathol. 2011 Nov;31(5 Suppl):S27-31
pubmed: 22054452
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Gastrointest Endosc. 2014 Aug;80(2):253-9
pubmed: 24613579
Cancer Manag Res. 2019 Apr 10;11:3009-3020
pubmed: 31114348
Ann Transl Med. 2019 Jan;7(1):16
pubmed: 30788363
Ann Surg. 2019 Dec;270(6):1096-1102
pubmed: 29995679
Ann Oncol. 2010 Jan;21(1):152-60
pubmed: 19622590
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Dig Surg. 2006;23(5-6):313-8
pubmed: 17164543
Gastrointest Endosc. 2006 Apr;63(4):570-80
pubmed: 16564854
Gastric Cancer. 2017 Mar;20(2):226-234
pubmed: 26924751
Ann Surg. 2010 Apr;251(4):640-6
pubmed: 20224369
Gastroenterology. 2020 Feb;158(3):693-702
pubmed: 31816298
J Gastric Cancer. 2012 Jun;12(2):55-62
pubmed: 22792517
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Ann Surg Oncol. 2015 Sep;22(9):2965-71
pubmed: 25631065
Am J Surg Pathol. 1999 May;23(5):511-8
pubmed: 10328081
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Ann Surg Oncol. 2012 Jul;19(7):2088-94
pubmed: 22395977
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
J Cancer. 2019 Jun 2;10(14):3145-3153
pubmed: 31289585
Cancer. 2000 Dec 1;89(11):2237-46
pubmed: 11147594
Lancet. 1997 Jun 14;349(9067):1725-9
pubmed: 9193382
Cancer Causes Control. 2013 Feb;24(2):217-31
pubmed: 23224270
J Clin Oncol. 2006 May 10;24(14):2188-96
pubmed: 16682738
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686

Auteurs

Joshua Tseng (J)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

James P Miller (JP)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Jeffrey Johnson (J)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Kevin Waters (K)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Alexandra Gangi (A)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Jun Gong (J)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Miguel Burch (M)

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Classifications MeSH